. 2021 Jun 13;9(6):647. doi: 10.3390/vaccines9060647

Table 1.

Approved Vaccine-Based Therapies in Malignancies.

Author (Date)—Study Name	Treatment Regimen	Total Patients	Patient Population	ORR/CR	mRFS (Months) HR, p-Value	mOS (Months) HR, p-Value
Lamm et al., (1991), SWOG 8507 [25]	Intravesicular BCG vs. intravesicular doxorubicin	262	Ta, T1, in situ transitional cell carcinoma of bladder	NR/70%	22.4 vs. 10.4	NR
Lamm et al., (1991), SWOG 8507 [25]	Intravesicular BCG vs. intravesicular doxorubicin	262	Ta, T1, in situ transitional cell carcinoma of bladder	NR/34%	NR, p = 0.015	NR
Lamm et al., (2000), SWOG 8507 [26]	Maintenance intravesicular BCG vs. placebo	384	Ta, T1, in situ transitional cell carcinoma of bladder	NR	76.8 vs. 35.7	NR
Lamm et al., (2000), SWOG 8507 [26]	Maintenance intravesicular BCG vs. placebo	384	Ta, T1, in situ transitional cell carcinoma of bladder	NR	NR, p < 0.0001	NR
Small et al., (2006), IMPACT [28]	Sipuleucel-T vs. placebo	512	Metastatic hormone-refractory prostate cancer	NR	11.7 vs. 10.0	25.9 vs. 21.4
Small et al., (2006), IMPACT [28]	Sipuleucel-T vs. placebo	512	Metastatic hormone-refractory prostate cancer	NR	NR, p = 0.052	NR, p = 0.01
Andtbacka et al., (2015) [29]	Talimogene laherparepvec vs. GM-CSF	436	Unresectable stage IIIB/C and stage IV melanoma	26%/10.8%	NR	23.3 vs. 18.9
Andtbacka et al., (2015) [29]	Talimogene laherparepvec vs. GM-CSF	436	Unresectable stage IIIB/C and stage IV melanoma	5.7%/<1%	NR	HR 0.79, p = 0.51

NR: not reported; NE: not estimable; GM-CSF: granulocyte macrophage colony-stimulating factor.